GLP1 RA Reverses the Harmful Association of Body Weight Variability with CVD Outcomes Across Different Metabolic Profiles

Authors

Sarpong Boateng, Internal Medicine, Bridgeport Hospital/Yale New Haven Health, Bridgeport, USA.Follow
Yussif Issaka MD, Department of Internal Medicine, Yale New Haven HealthFollow
Basile Njei, Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar St, New Haven, CT, 06520, USA. basile.njei@yale.edu.

Document Type

Conference Proceeding

Abstract

This study aimed to investigate the impact of GLP1 RA on this known negative relationship between BMI variability and cardiovascular (CVD) outcomes across different metabolic profiles.

Publication Date

5-2025

Recommended Citation

Boateng, Sarpong; Issaka, Yussif MD; and Njei, Basile, "GLP1 RA Reverses the Harmful Association of Body Weight Variability with CVD Outcomes Across Different Metabolic Profiles" (2025). Posters. 89.
https://scholar.bridgeporthospital.org/poster_presentations/89